Drugs /

mm-310

Back to Drugs List

Overview

NCI Definition [1]:
A formulation containing nanoparticles composed of liposomes that are conjugated to scFv antibody fragments directed against the ephrin receptor A2 (EphA2; Ephrin A2) and a proprietary prodrug of docetaxel, a poorly water-soluble, second-generation taxane analog, with potential antineoplastic activity. Upon intravenous administration of the anti-EphA2 antibody-directed liposomal docetaxel prodrug MM-310, the anti-EphA2 moiety selectively targets and binds to cells expressing EphI3:I12A2. Following accumulation of MM-310, docetaxel is slowly released from MM-310 and accumulates at the tumor site due to the unique characteristics of the tumor vasculature. In turn, docetaxel is taken up by tumor cells, where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and the induction of cell death. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth; its expression is associated with poor prognosis. Compared to free docetaxel, MM-310 increases docetaxel's half-life, and provides enhanced and specific accumulation in EphA2-expressing tumors, thereby increasing docetaxel's efficacy while lowering its systemic toxicity.

Clinical Trials

View Clinical Trials for mm-310

Mm-310 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating mm-310, 1 is phase 1 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for mm-310 clinical trials.

Adenocarcinoma of the gastroesophageal junction, breast carcinoma, and endometrial carcinoma are the most common diseases being investigated in mm-310 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mm-310
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mm-310 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
nti-epha2 antibody-directed liposomal docetaxel prodrug mm-310, anti-epha2 antibody-targeted nanoliposome mm-310, mm310, mm 310, epha2-targeted docetaxel nanoliposome mm-310, anti-epha2 docetaxel-based nanoliposome mm-310
Drug Target(s) [2]:
EPHA2
NCIT ID [1]:
C136981

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.